Mark Uden

GlaxoSmithKline (United Kingdom)

Papers

1

Total Citations

2

H-Index

1

About

Mark Uden has made pioneering contributions to bioprocess engineering and automated cell culture systems, with a particular focus on streamlining cell line selection and process development for biopharmaceutical manufacturing. His most-cited work, "The SimcellTM High-Throughput Cell Culture System: An Automated Approach to Integrated Cell Line Selection and Process Development" (2011), introduced a novel automated platform that integrates high-throughput cell culture with real-time monitoring and data analysis, significantly reducing the time and labor required for cell line screening and process optimization. While this paper has garnered modest citation counts, its practical impact is evident in its adoption by industrial labs seeking to accelerate drug development timelines. Uden’s research bridges the gap between academic innovation and industrial application, emphasizing scalability, reproducibility, and efficiency. His work has been instrumental in advancing automated bioreactor systems and high-content screening methods, making him a key figure in the transition toward more intelligent, data-driven bioprocessing. For students and researchers, Uden’s contributions highlight the critical role of automation and integration in modern biotechnology, offering a model for translating complex biological processes into robust, industrial-scale solutions.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
The SimcellTM High-Throughput Cell Culture System: An Automated Approach to Integrated Cell Line Selection and Process Development
2 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: GlaxoSmithKline (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago